NanoViricides (NNVC) 10-Q 14 May 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2021	May 14, 2021
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	0001379006
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		11,505,000
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2021	Jun. 30, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 22,899,518	$ 13,708,594
Prepaid expenses	331,551	277,063
Total current assets	23,231,069	13,985,657
PROPERTY AND EQUIPMENT
Property and equipment	14,249,024	14,100,815
Accumulated depreciation	(5,074,669)	(4,556,384)
Property and equipment, net	9,174,355	9,544,431
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(106,768)	(100,566)
Trademark and patents, net	352,186	358,388
OTHER ASSETS
Deferred financing costs		12,190
Security deposits	3,515	3,515
Service agreements		10,158
Other assets	3,515	25,863
Total assets	32,761,125	23,914,339
CURRENT LIABILITIES:
Mortgage note payable - related party		1,081,987
Accounts payable	98,235	380,727
Accounts payable - related party	583,075	561,580
Loan payable	165,806	62,843
Accrued expenses	24,228	69,240
Total current liabilities	871,344	2,156,377
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 11,504,693 and 9,083,414 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively	11,505	9,083
Additional paid-in capital	144,190,346	127,311,634
Accumulated deficit	(112,312,441)	(105,563,124)
Total stockholders' equity	31,889,781	21,757,962
Total liabilities and stockholders' equity	32,761,125	23,914,339
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 371,103 and 368,602 shares issued and outstanding, at March 31, 2021 and June 30, 2020, respectively	$ 371	$ 369

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Jun. 30, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	11,504,693	9,083,414
Common stock, shares, outstanding	11,504,693	9,083,414
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	371,103	368,602
Preferred stock, shares outstanding	371,103	368,602

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
OPERATING EXPENSES
Research and development	$ 1,464,177	$ 1,134,132	$ 4,530,448	$ 3,628,622
General and administrative	643,358	1,408,231	2,139,392	2,536,050
Total operating expenses	2,107,535	2,542,363	6,669,840	6,164,672
LOSS FROM OPERATIONS	(2,107,535)	(2,542,363)	(6,669,840)	(6,164,672)
OTHER INCOME (EXPENSE)
Interest income	2,021	9,264	6,267	15,265
Interest expense	(2,516)	(44,937)	(83,718)	(49,068)
Loss on disposal of property and equipment			(2,026)	0
Gain on warrant settlement		614,494	0	614,494
Loss on issuance of Series A preferred stock for accounts payable - related party			0	(142,669)
Change in fair value of derivative liability		(6,119,762)		(5,845,313)
Other (expense) income	(495)	(5,540,941)	(79,477)	(5,407,291)
LOSS BEFORE INCOME TAX PROVISION	(2,108,030)	(8,083,304)	(6,749,317)	(11,571,963)
INCOME TAX PROVISION	0	0	0	0
NET LOSS	$ (2,108,030)	$ (8,083,304)	$ (6,749,317)	$ (11,571,963)
NET LOSS PER COMMON SHARE
Net loss per common share- basic and diluted	$ (0.19)	$ (1.24)	$ (0.63)	$ (2.45)
Weighted average common shares outstanding
Weighted average common shares outstanding - basic and diluted	10,953,052	6,518,077	10,700,405	4,732,514

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2019	$ 256	$ 3,845	$ 102,712,845	$ (92,116,586)	$ 10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Series A Preferred Stock issued for employee stock compensation			51,398		51,398
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,201
Warrants issued to Scientific Advisory Board			908		908
Common shares issued for Directors fees		$ 3	11,247		11,250
Common shares issued for Directors fees (in shares)		2,553
Net loss				(1,561,133)	(1,561,133)
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Balance at Jun. 30, 2019	$ 256	$ 3,845	102,712,845	(92,116,586)	10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Net loss					(11,571,963)
Balance at Mar. 31, 2020	$ 368	$ 7,673	117,995,269	(103,688,549)	14,314,761
Balance (in shares) at Mar. 31, 2020	368,215	7,673,357
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Series A Preferred Stock issued for employee stock compensation			49,394		49,394
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Series A Preferred Stock issued for accounts payable-related party	$ 100		392,569		392,669
Series A Preferred Stock issued for accounts payable-related party (in Shares)	100,000
Series A Preferred Stock issued for loan origination fee	$ 10		39,291		39,301
Series A Preferred Stock issued for loan origination fee (in shares)	10,000
Common stock issued for consulting and legal services rendered		$ 12	26,988		27,000
Common stock issued for consulting and legal services rendered (in shares)		11,932
Warrants issued to Scientific Advisory Board			533		533
Common shares issued for Directors fees		$ 5	11,245		11,250
Common shares issued for Directors fees (in shares)		4,965
Net loss				(1,927,526)	(1,927,526)
Balance at Dec. 31, 2019	$ 366	$ 3,871	103,323,412	(95,605,245)	7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572
Series A Preferred Stock issued for employee stock compensation	$ 2		73,465		73,467
Series A Preferred Stock issued for employee stock compensation (in shares)	1,727
Common stock issued for accounts payable		$ 9	51,991		52,000
Common stock issued for accounts payable (In shares)		8,467
Common stock issued in exchange for warrants		$ 677	5,721,866		5,722,543
Common stock issued in exchange for warrants (In shares)		677,224
Common stock issued upon cashless exercise of warrants		$ 180	1,153,701		1,153,881
Common stock issued upon cashless exercise of warrants (In shares)		180,087
Net proceeds from issuance of common stock in connection with equity financings		$ 2,875	7,454,700		7,457,575
Net proceeds from issuance of common stock in connection with equity financings (in shares)		2,875,000
Common stock issued for consulting and legal services rendered		$ 56	173,194		173,250
Common stock issued for consulting and legal services rendered (in shares)		56,854
Warrants issued to Scientific Advisory Board			2,444		2,444
Common stock issued for employee compensation		$ 4	29,247		29,251
Common stock issued for employee compensation (in shares)		3,572
Common shares issued for Directors fees		$ 1	11,249		11,250
Common shares issued for Directors fees (in shares)		1,581
Net loss				(8,083,304)	(8,083,304)
Balance at Mar. 31, 2020	$ 368	$ 7,673	117,995,269	(103,688,549)	14,314,761
Balance (in shares) at Mar. 31, 2020	368,215	7,673,357
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Series A Preferred Stock issued for employee stock compensation	$ 0	$ 0	53,098	0	53,098
Series A Preferred Stock issued for employee stock compensation (in shares)	387	0
Net proceeds from issuance of common stock in connection with equity financings		$ 1,576	10,440,640		10,442,216
Net proceeds from issuance of common stock in connection with equity financings (in shares)		1,575,342
Common stock issued for consulting and legal services rendered		$ 5	26,995		27,000
Common stock issued for consulting and legal services rendered (in shares)		5,135
Warrants issued to Scientific Advisory Board			1,986		1,986
Common shares issued for Directors fees		$ 2	11,248		11,250
Common shares issued for Directors fees (in shares)		2,040
Net loss				(2,311,233)	(2,311,233)
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Net loss					(6,749,317)
Balance at Mar. 31, 2021	$ 371	$ 11,505	144,190,346	(112,312,441)	31,889,781
Balance (in shares) at Mar. 31, 2021	371,103	11,504,693
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Series A Preferred Stock issued for employee stock compensation			50,602		50,602
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 7	26,993		27,000
Common stock issued for consulting and legal services rendered (in shares)		7,411
Warrants issued to Scientific Advisory Board			1,215		1,215
Common shares issued for Directors fees		$ 4	14,996		15,000
Common shares issued for Directors fees (in shares)		4,106
Net loss				(2,330,054)	(2,330,054)
Balance at Dec. 31, 2020	$ 369	$ 10,677	137,939,407	(110,204,411)	27,746,042
Balance (in shares) at Dec. 31, 2020	369,376	10,677,448
Series A Preferred Stock issued for employee stock compensation	$ 2		71,498		71,500
Series A Preferred Stock issued for employee stock compensation (in shares)	1,727
Net proceeds from issuance of common stock in connection with equity financings		$ 815	6,120,666		6,121,481
Net proceeds from issuance of common stock in connection with equity financings (in shares)		814,242
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,131
Warrants issued to Scientific Advisory Board			1,750		1,750
Common stock issued for employee compensation		$ 4	15,034		15,038
Common stock issued for employee compensation (in shares)		3,572
Common shares issued for Directors fees		$ 3	14,997		15,000
Common shares issued for Directors fees (in shares)		3,300
Net loss				(2,108,030)	(2,108,030)
Balance at Mar. 31, 2021	$ 371	$ 11,505	$ 144,190,346	$ (112,312,441)	$ 31,889,781
Balance (in shares) at Mar. 31, 2021	371,103	11,504,693

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,749,317)	$ (11,571,963)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	175,200	174,259
Loss on issuance of preferred shares for accounts payable- related party	0	142,669
Common shares issued as compensation and for services	137,288	290,250
Warrants granted to Scientific Advisory Board	4,951	3,885
Depreciation	522,172	518,536
Amortization of loan origination fees	18,013	11,463
Amortization	6,202	6,204
Change in fair value of derivative liabilities	0	5,845,313
Loss on disposal of property and equipment	2,026	0
Write-off of deferred financing costs	12,190	0
Gain on warrant settlement	0	(614,494)
Changes in operating assets and liabilities:
Prepaid expenses	180,988	93,615
Other assets	10,158	11,688
Accounts payable	(282,492)	152,281
Accounts payable - related party	21,495	4,372
Accrued expenses	(45,012)	(25,313)
NET CASH USED IN OPERATING ACTIVITIES	(5,986,138)	(4,957,235)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(154,122)	(4,139)
NET CASH USED IN FINANCING ACTIVITIES	(154,122)	(4,139)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	16,563,697	7,457,575
Proceeds from note payable -related party	0	1,100,000
Payment of note payable - related party	(1,100,000)	0
Proceeds from loan payable	0	0
Payment of loan payable	(132,513)	(45,878)
NET CASH PROVIDED BY FINANCING ACTIVITIES	15,331,184	8,511,697
NET CHANGE IN CASH AND CASH EQUIVALENTS	9,190,924	3,550,323
Cash and cash equivalents at beginning of period	13,708,594	2,555,207
Cash and cash equivalents at end of period	22,899,518	6,105,530
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	3,171	0
Non-cash Financing and Investing Activities:
Directors and Officers Insurance Financed Through loan	235,476	155,173
Cashless exercise of warrants reclassed from warrant liability to common stock	0	1,153,881
Series A preferred stock issued for accounts payable-related party	0	250,000
Series A preferred stock issued for loan origination fee	0	39,301
Common stock issued to settle accounts payable	$ 0	$ 52,000

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Mar. 31, 2021
Organization and Nature of Business
Organization and Nature of Business	Note 1 – Organization and Nature of Business NanoViricides, Inc. (the “Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. The Company has several drugs in various stages of early development. COVID-19 has become our lead drug program due to the necessity of responding to the pandemic. The Company began development of a drug to treat COVID-19 patients just as the cases of the novel disease were being reported from China. The Company’s drug candidates for COVID-19 successfully entered core safety pharmacology studies required prior to any human clinical trials around October/November, 2020. The studies were completed in January and February 2021, and the Company has received draft reports from the external Contract Research Organization (CRO). The final quality audited reports on these studies are expected soon and will be required for an Investigational New Drug (IND) Application. The Company is currently working on a pre-IND application to the US Food and Drug Administration (FDA) to seek guidance for an IND. The Company is also involved with tasks needed for setting up and executing human clinical trials for our COVID-19 drug candidates assuming that the IND is approved by the US FDA. As of March 31, 2021, there are 10 COVID-19 drugs that have received Emergency Use Authorization (EUA) and one drug that has received full approval (remdesivir) from the US FDA (https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#dashboard). In addition, there are at least three vaccines licensed in the USA and several more are in use internationally. Apart from remdesivir and antibodies, there are very few drugs with direct antiviral effect that have EUA or are in clinical trials. Internationally, virus variants have continued to emerge with resistance to drugs and vaccines. Scientists believe it is only a matter of time before escape variants against existing vaccines and therapeutics become commonplace. Thus the need for therapeutics that the virus would not escape by mutations, such as the broad-spectrum, pan-coronavirus nanoviricides drug candidates, remains unmet. The Company plans on re-engaging our other lead antiviral program against herpes viruses, i.e. the HerpeCide™ program, as soon as it becomes feasible to conduct the corresponding antiviral human clinical studies. In the HerpeCide program alone, we have drug candidates against at least five indications at different stages of development. Of these, the Company is advancing the shingles drug candidate towards human clinical trials. The IND-enabling Safety/Toxicology studies required for doing so have been completed and we were in the process of preparing an IND application for this drug candidate when the SRAS-CoV-2 virus struck, whereupon we pivoted our efforts to respond to the threat of what has now become the COVID-19 pandemic. In addition, our drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). There are estimated to be approximately 120,000-150,000 annual chickenpox cases in the USA in the post-vaccination-era, i.e. since childhood vaccination with the live attenuated varicella virus Oka strain has become standard. In addition, we have drugs in development against all influenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have broad, exclusive licenses. The first license agreement we executed with TheraCour on September 1, 2005 (“Exclusive License Agreement”), gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. In addition, on November 1, 2019, the Company entered into a world-wide, exclusive, sub-licensable, license (“VZV License Agreement”) to use, promote, offer for sale, import, export, sell and distribute drugs that treat VZV infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company’s Series A Convertible Preferred Stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials. The Company has requested TheraCour for a license in the field of coronaviruses. A Memorandum of Understanding (“MOU”) towards licensing this field has been agreed to and executed on June 8, 2020. The MOU was extended until June 15, 2021 with a First Amendment on April 21, 2021, which amendment was given effect as of August 31, 2020. The amendment clarifies that the rights to milestone payments will remain effective even if the final agreement is signed after meeting a milestone. The MOU provides a limited license to the Company for the entire application of human coronavirus infections (the “COVID License Agreement”), while the full license is being perfected. In furtherance of the COVID License Agreement, the Company has appointed a third party consulting firm for independent evaluation of this market space. The terms of the COVID License Agreement, except as otherwise specified in the MOU, is expected to be generally consistent with the terms of the VZV License Agreement dated November 1, 2019, and shall include consistent milestone payments, royalties and sublicense and income derived from grants and contracts.

Liquidity

Liquidity	9 Months Ended
	Mar. 31, 2021
Liquidity
Liquidity	Note 2 - Liquidity The Company’s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company has an accumulated deficit at March 31, 2021 of approximately $112.3 million and a net loss of approximately $6.7 million and net cash used in operating activities of approximately $6.0 million for the nine months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of March 31, 2021, the Company had available cash and cash equivalents of approximately $22.9 million. Since the onset of the COVID-19 pandemic, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely, taking the COVID-19 drug candidate against SARS-CoV-2 into human clinical trials. The prior lead program for a shingles drug will follow the COVID-19 drug program. On July 8, 2020 the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. (“Kingswood”). The offering was consummated on July 10, 2020, whereby the Company sold 1,369,863 shares of common stock and a fully exercised Underwriters’ over-allotment option of 205,479 additional shares at the public offering price of $7.30 per share. No warrants were issued in this offering. The net proceeds to the Company from the offering was approximately $10.4 million after deducting underwriting discounts and commissions and other estimated offering expenses. On July 31, 2020, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and Kingswood (each a “Sales Agent” and collectively, the “Sales Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of common stock (the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATM Offering”). Sales pursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Company’s common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. The Company is not obligated to make any sales of common stock under the Sales Agreement and the Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The Company will pay a commission rate of up to 3.5% of the gross sales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales Agents an amount not to exceed $2,500 per quarter during the term of the Sales Agreement for legal fees to be incurred by the Sales Agents. The Company has also agreed pursuant to the Sales Agreement to provide each Sales Agent with customary indemnification and contribution rights. On March 2, 2021 the Company sold 814,242 shares of common stock at an average price of $7.83 under the Sales Agreement with B. Riley Securites, Inc. The net proceeds to the Company from the offering was approximately $6.1 million after deducting underwriting discounts and commissions and other offering expenses. The Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones, the Company’s ability to raise additional funds in the public markets would be enhanced. The Company has not experienced a direct financial adverse impact of the effects of the Coronavirus (COVID-19) pandemic. However, the pandemic required the Company to reorganize its priorities, because of the impact on the ability to conduct antiviral drug trials for our then lead program for Shingles drug treatment. While clinical trials were in general adversely affected, the ability to enroll patients into the shingles antiviral drug clinical trial with the desired inclusion criteria became limited due to the widespread coronavirus infection. The shingles clinical trial design and conduct would also become more complex. The emergence of widespread health emergencies due to COVID-19 have led to regional quarantines, shutdowns, shortages, disruptions of supply chains, and economic instability. The impact of COVID-19 on the financial markets and the overall economy are highly uncertain and cannot be predicted at this time. Though the Company has not experienced a direct financial impact, if the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds, in the future, may be materially adversely affected. Management believes that the Company’s existing resources will be sufficient to fund its planned operations and expenditures for at least the next twelve months from the issuance of these financial statements. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue which reaches a level sufficient to provide self-sustaining cash flows. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10‑K for the fiscal year ended June 30, 2020 filed with the SEC on October 13, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2020 filed on October 13, 2020. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2021 March 31, 2020 Options 5,000 5,000 Warrants 9,146 22,505 Total potentially outstanding dilutive common shares 14,146 27,505 The Company has 371,103 shares of Series A preferred stock outstanding as of March 31, 2021. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a change of control event, the Series A preferred stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At March 31, 2021, the number of potentially dilutive shares of the Company’s common stock into which these Series A preferred shares can be converted into is 1,298,861 and is not included in diluted earnings per share since the shares are contingently convertible only upon a change of control.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2021
Related Party Transactions
Related Party Transactions	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Dr. Anil R. Diwan Chairman, President, CEO, significant stockholder and Director TheraCour Pharma, Inc. (“TheraCour”) An entity owned and controlled by Dr. Anil Diwan For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2021 2020 2021 2020 Property and Equipment During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 84,466 $ — $ 87,026 $ 4,139 As of March 31, June 30, 2021 2020 Account Payable – Related Party Pursuant to an Exclusive License Agreement with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. On November 1, 2019, the Company entered into the VZV Licensing Agreement with TheraCour. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of certain direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour and; (4) to pay an advance payment equal to twice the amount of the previous months invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Company agreed to enter into an agreement with TheraCour for a waiver of two months worth of prepaid balance in advance of anticipated invoicing, due under prior agreements until the filing of an IND and the application of the then current advance as a credit against current open invoices. Additionally, TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. Accounts payable due TheraCour at March 31, 2021 was $1,074,075 which was offset by a two month advance (see above) of $491,000. There was no advance at June 30, 2020. $ 583,075 $ 561,580 For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2021 2020 2021 2020 Research and Development Costs Paid to Related Party Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2021 and June 30, 2020 $ 706,537 $ 601,016 $ 1,961,603 $ 1,720,311 Mortgage Note Payable - Related Party On December 16, 2019, the Company entered into an Open End Mortgage Note (the “Note”) with Dr. Anil Diwan, the Company’s founder, Chairman, President and CEO, to loan the Company up to $2,000,000 in two tranches of $1,000,000 (the “Loan”). The Note was paid off on December 31, 2020. The Note bore interest at the rate of 12% per annum and was secured by a mortgage granted against the Company’s headquarters. Dr. Anil Diwan received 10,000 shares of the Company’s Series A preferred stock as a loan origination fee which was amortized over the one year term of the loan using the effective interest method. The fair value of the 10,000 shares of the Company’s Series A preferred stock when issued on December 16, 2019 was $39,301. The Series A preferred stock fair value is based on the greater of the i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. For the assumptions used in calculating the fair value of the preferred shares, the conversion of the shares is triggered by a change of control. Amortization expense on the loan origination fee for the three and nine months ended March 31, 2021 was $0 and $18,013, respectively, and $9,825 and $11,463 for the three and nine months ended March 31, 2020 respectively. The Company had drawn down $1.1 million of this loan. Interest was payable only on the amount drawn down. The lender had escrowed $132,000 of interest payable pursuant to the Loan. For the three and nine months ended March 31, 2021, the Company incurred interest expense of $0 and $62,773, respectively, and $33,367 and $35,860 for the three and nine months ended March 31, 2020 respectively, which reduced the interest escrow balance included in prepaid expenses.

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2021
Property and Equipment
Property and Equipment	Note 5 - Property and Equipment Property and equipment, stated at cost, less accumulated depreciation consisted of the following: March 31, June 30, 2021 2020 GMP Facility $ 8,040,411 $ 8,020,471 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,885,223 5,756,956 Total Property and Equipment 14,249,024 14,100,815 Less Accumulated Depreciation (5,074,669) (4,556,384) Property and Equipment, Net $ 9,174,355 $ 9,544,431 Depreciation expense for the three months ended March 31, 2021 and 2020 were $174,076 and $172,862, respectively, and for the nine months ended March 31, 2021 and 2020 were $522,172 and $518,536, respectively.

Trademark and Patents

Trademark and Patents	9 Months Ended
	Mar. 31, 2021
Trademarks and Patents
Trademarks and Patents	Note 6 - Trademark and Patents Trademark and patents, stated at cost, less accumulated amortization consisted of the following: March 31, June 30, 2021 2020 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (106,768) (100,566) Trademarks and Patents, Net $ 352,186 $ 358,388 Amortization expense amounted to $2,067 and $2,069 for the three months ended March 31, 2021 and 2020, respectively, and for the nine months ended March 31, 2021 and 2020 were $6,202 and $6,204, respectively.

Accrued expenses

Accrued expenses	9 Months Ended
	Mar. 31, 2021
Accrued expenses
Accrued expenses	Note 7 - Accrued expenses Accrued expenses consisted of the following: March 31, June 30, 2021 2020 Severance payment $ — $ 21,000 Accrued payroll 24,228 38,240 Consultant — 10,000 Accrued Expenses $ 24,228 $ 69,240

Loan Payable

Loan Payable	9 Months Ended
	Mar. 31, 2021
Loan Payable
Loan Payable	Note 8 – Loan Payable The Company financed its Directors and Officers liability insurance policies through BankDirect for the periods January 1, 2021 to December 31, 2021 and January 1, 2020 to December 31, 2020. The original loan balance as of January 1, 2021 and January 1, 2020 was $235,476 and $155,173, respectively, payable at the rate of $24,062 and $15,874 monthly including interest at an annual rate of 4.74% and 5%, respectively, through October of each year. At March 31, 2021 and June 30, 2020 the loan balance was $165,806 and $62,843, respectively. For the three and nine months ended March 31, 2021 the Company incurred interest expense of $2,516 and $3,282, respectively. For both the three and nine months ended March 31, 2020 the Company incurred interest expense of $1,745.

Equity Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2021
Equity Transactions
Equity Transactions	Note 9 - Equity Transactions On July 11, 2018 the Board of Directors approved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 shares of the Company’s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June 30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the Series A preferred stock of $45,654 and $136,962 for the three and nine months ended March 31, 2021. The balance of $45,654 will be recognized as the remaining 4,375 shares vest and service is rendered for the year ended June 30, 2021. On July 8, 2020 the Company entered into an Underwriting Agreement with Kingswood. Pursuant to the terms and conditions of the Underwriting Agreement, the Company agreed to issue and sell 1,369,863 shares of our common stock, par value $0.001 per share (the “Underwritten Shares”), at a price to the public of $7.30 per share. Pursuant to the Underwriting Agreement, the Company also granted the underwriter an option to purchase up to an additional 205,479 shares of common stock (together with the Underwritten Shares, the “Shares”) within 45 days after the date of the Underwriting Agreement to cover over-allotments, if any. The shares were issued pursuant to a prospectus supplement dated July 8, 2020 which was filed with the Securities and Exchange Commission on July 9, 2020 in connection with a takedown from the Company’s shelf registration statement on Form S-3, as amended (File No. 333-237370), which became effective on April 2, 2020 and the base prospectus dated April 2, 2020 contained in that registration statement. The offering was consummated on July 10, 2020, whereby the Company sold 1,369,863 shares of common stock and a fully exercised Underwriters’ overallotment of 205,479 additional shares at the public offering price of $7.30 per share. The net proceeds to the Company from the offering was approximately $10.4 million after placement agent fees and other estimated offering expenses. The Company accounted for the proceeds of the Offering at July 10, 2020 as follows: Gross proceeds $ 11,499,997 Less: offering costs and expenses (1,057,781) Net proceeds from issuance of common stock $ 10,442,216 On July 31, 2020, the Company entered into a Sales Agreement with the Sales Agents, pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of common stock having an aggregate offering price of up to $50 million On March 2, 2021, the Company sold 814,242 shares of common stock at an average price of $7.83 per share. The shares were issued pursuant to a prospectus supplement dated December 3, 2020 filed with the Securities and Exchange Commission on December 10, 2020 in connection with the Company’s shelf registration statement on Form S-3, as amended (File No. 333-237370), which became effective on April 2, 2020. The net proceeds to the Company from the offering was approximately $6.1 million after placement agent fees and other estimated offering expenses. The Company accounted for the proceeds of the Offering at July 10, 2020 as follows: Gross proceeds $ 6,374,211 Less: offering costs and expenses (252,730) Net proceeds from issuance of common stock $ 6,121,481 For the three and nine months ended March 31, 2021, the Company’s Board of Directors authorized the issuance of 1,727 and 2,501, respectively fully vested shares of its Series A preferred stock for employee compensation. The Company recorded expense of $25,846 and $38,238, respectively for the three and nine months ended March 31, 2021 related to these issuances. The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2020 129 $ 3,155 8/31/2020 129 2,391 9/30/2020 129 1,898 10/31/2020 129 1,749 11/30/2020 129 1,596 12/31/2020 129 1,603 01/31/2021 129 1,632 02/28/2021 129 2,153 03/01/2021 1,340 19,744 03/31/2021 129 2,317 2,501 $ 38,238 There is currently no market for the shares of Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferred stock granted to various employees and others on the date of grant. The Series A preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a change of control. The common stock price for the nine months ended March 31, 2021 was in the range $2.87 to $9.97. During the nine months ended March 31, 2021, the Scientific Advisory Board was granted in August 2020 fully vested warrants to purchase 572 shares of common stock with an exercise price of $6.86 per share expiring in August 2024 and in November 2020 fully vested warrants to purchase 572 shares of common stock with an exercise price of $4.19 per share expiring in November 2024 and in February 2021 fully vested warrants to purchase 572 shares of common stock with an exercise price of $6.05 per share expiring in February 2025. The fair value of the warrants was $1,750 for the three months ended March 31, 2021 and $4,951 for the nine months ended March 31, 2021 and was recorded as consulting expense. The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) Expected volatility 91.1-91.5 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) .24-.35 % For the three and nine months ended March 31, 2021, the Company’s Board of Directors authorized the issuance of 6,131 and 18,677, respectively, fully vested shares of its common stock with a restrictive legend for consulting services. The Company recorded expense of $27,000 and $81,000, respectively, for the three and nine months ended March 31, 2021, which was the fair value on the dates of issuance. For the three and nine months ended March 31, 2021, the Company’s Board of Directors authorized the issuance of 3,300 and 9,446, respectively, fully vested shares of its common stock with a restrictive legend for Director Services. The Company recorded an expense of $15,000 and $41,250, respectively, for the three and nine months ended March 31, 2021, which was the fair value on the dates of issuance. For both the three and nine months ended March 31, 2021, the Company’s Board of Directors authorized the issuance of 3,572 of fully vested shares of its common stock for employee compensation. The Company recorded an expense of $15,038 for both the three and nine months ended March 31, 2021 which was the fair value on the date of issuance.

Stock Warrants and Options

Stock Warrants and Options	9 Months Ended
	Mar. 31, 2021
Stock Warrants and Options
Stock Warrants and Options	Note 10 - Stock Warrants and Options Stock Warrants Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2020 22,218 $ 30.82 2.28 $ 4,533 Granted 1,716 5.36 — — Expired 14,788 39.16 — — Outstanding and exercisable at March 31, 2021 9,146 $ 12.34 2.00 $ 1,497 Of the above warrants, 569 expire in fiscal year ending June 30, 2021; 2,287 expire in fiscal year ending June 30, 2022, 2,287 expire in fiscal year ending June 30, 2023, 2,287 warrants expire in the fiscal year ending June 30, 2024 and 1,716 warrants expire in the fiscal year ending June 30, 2025. Stock Options Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Options Shares ($) (years) ($) Outstanding and exercisable at June 30, 2020 5,000 $ 10.00 1.16 $ — Granted — — — — Outstanding and exercisable at March 31, 2021 5,000 $ 10.00 .42 — The options expire on August 31, 2021.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	Note 11 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Anil Diwan, President, CEO and Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three years. Dr. Anil Diwan will be paid an annual base salary of $400,000. Additionally, Dr. Anil Diwan was awarded a grant of 26,250 shares of the Company’s Series A preferred stock. 8,750 shares vest equally on June 30, 2019, 2020 and 2021. Any unvested shares are subject to forfeiture. On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and will issue an additional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date of the agreement. The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $150,000. In addition, the Company issued 1,786 shares of common stock upon entering into the agreement, and will issue an additional 1,786 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. On May 30, 2013, the Company entered into an employment agreement with Meeta Vyas, wife of our President, CEO and Chairman of the Board, to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $9,000 per month and 129 shares of Series A preferred stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The agreement is renewable on an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangements and employment agreements. License Agreements The Company is dependent upon its license agreements with TheraCour (See Notes 1 and 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. On November 1, 2019, the Company entered into the VZV Licensing Agreement with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company’s Series A preferred stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials. On June 8, 2020, the Company executed a MOU with TheraCour that provides a limited license to the Company for the entire application of human coronavirus infections, while the full license is being perfected. On April 21, 2021 the MOU was extended. The Company has appointed a third party consulting firm for independent evaluation of this market space. Dr. Anil Diwan is recused from these discussions due to a conflict of interest. The terms of the COVID License Agreement, except as otherwise specified in the MOU, is expected to be generally consistent with the VZV License Agreement dated November 1, 2019, and shall include consistent milestone payments, royalties and sublicense and income derived from grants and contracts.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation - Interim Financial Information	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10‑K for the fiscal year ended June 30, 2020 filed with the SEC on October 13, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2020 filed on October 13, 2020.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2021 March 31, 2020 Options 5,000 5,000 Warrants 9,146 22,505 Total potentially outstanding dilutive common shares 14,146 27,505 The Company has 371,103 shares of Series A preferred stock outstanding as of March 31, 2021. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a change of control event, the Series A preferred stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At March 31, 2021, the number of potentially dilutive shares of the Company’s common stock into which these Series A preferred shares can be converted into is 1,298,861 and is not included in diluted earnings per share since the shares are contingently convertible only upon a change of control.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Schedule of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2021 March 31, 2020 Options 5,000 5,000 Warrants 9,146 22,505 Total potentially outstanding dilutive common shares 14,146 27,505

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Mar. 31, 2021
Related Party Transactions
Summary of related parties	Related Parties Relationship Dr. Anil R. Diwan Chairman, President, CEO, significant stockholder and Director TheraCour Pharma, Inc. (“TheraCour”) An entity owned and controlled by Dr. Anil Diwan For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2021 2020 2021 2020 Property and Equipment During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 84,466 $ — $ 87,026 $ 4,139 As of March 31, June 30, 2021 2020 Account Payable – Related Party Pursuant to an Exclusive License Agreement with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. On November 1, 2019, the Company entered into the VZV Licensing Agreement with TheraCour. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of certain direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour and; (4) to pay an advance payment equal to twice the amount of the previous months invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Company agreed to enter into an agreement with TheraCour for a waiver of two months worth of prepaid balance in advance of anticipated invoicing, due under prior agreements until the filing of an IND and the application of the then current advance as a credit against current open invoices. Additionally, TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. Accounts payable due TheraCour at March 31, 2021 was $1,074,075 which was offset by a two month advance (see above) of $491,000. There was no advance at June 30, 2020. $ 583,075 $ 561,580 For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2021 2020 2021 2020 Research and Development Costs Paid to Related Party Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2021 and June 30, 2020 $ 706,537 $ 601,016 $ 1,961,603 $ 1,720,311

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2021
Property and Equipment
Schedule of property and equipment	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: March 31, June 30, 2021 2020 GMP Facility $ 8,040,411 $ 8,020,471 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,885,223 5,756,956 Total Property and Equipment 14,249,024 14,100,815 Less Accumulated Depreciation (5,074,669) (4,556,384) Property and Equipment, Net $ 9,174,355 $ 9,544,431

Trademark and Patents (Tables)

Trademark and Patents (Tables)	9 Months Ended
	Mar. 31, 2021
Trademarks and Patents
Schedule of trademark and patents, stated at cost, less accumulated amortization	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: March 31, June 30, 2021 2020 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (106,768) (100,566) Trademarks and Patents, Net $ 352,186 $ 358,388

Accrued expenses (Tables)

Accrued expenses (Tables)	9 Months Ended
	Mar. 31, 2021
Accrued expenses
Schedule of accrued expenses	Accrued expenses consisted of the following: March 31, June 30, 2021 2020 Severance payment $ — $ 21,000 Accrued payroll 24,228 38,240 Consultant — 10,000 Accrued Expenses $ 24,228 $ 69,240

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Mar. 31, 2021
Schedule of estimation of estimated the fair value of the warrants granted	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) Expected volatility 91.1-91.5 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) .24-.35 %
Sales Agreement
Schedule of proceeds of the offering	The Company accounted for the proceeds of the Offering at July 10, 2020 as follows: Gross proceeds $ 6,374,211 Less: offering costs and expenses (252,730) Net proceeds from issuance of common stock $ 6,121,481
Underwriting option
Schedule of proceeds of the offering	The Company accounted for the proceeds of the Offering at July 10, 2020 as follows: Gross proceeds $ 11,499,997 Less: offering costs and expenses (1,057,781) Net proceeds from issuance of common stock $ 10,442,216
Series A Preferred stock
Schedule of fair value of Series A Preferred Stock	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2020 129 $ 3,155 8/31/2020 129 2,391 9/30/2020 129 1,898 10/31/2020 129 1,749 11/30/2020 129 1,596 12/31/2020 129 1,603 01/31/2021 129 1,632 02/28/2021 129 2,153 03/01/2021 1,340 19,744 03/31/2021 129 2,317 2,501 $ 38,238

Stock Warrants and Options (Tab

Stock Warrants and Options (Tables)	9 Months Ended
	Mar. 31, 2021
Equity Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Options Shares ($) (years) ($) Outstanding and exercisable at June 30, 2020 5,000 $ 10.00 1.16 $ — Granted — — — — Outstanding and exercisable at March 31, 2021 5,000 $ 10.00 .42 —
Stock Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2020 22,218 $ 30.82 2.28 $ 4,533 Granted 1,716 5.36 — — Expired 14,788 39.16 — — Outstanding and exercisable at March 31, 2021 9,146 $ 12.34 2.00 $ 1,497

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - USD ($)	Nov. 01, 2019	Mar. 31, 2021
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
TheraCour
Issuance of shares	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Percentage of Net Sales Allocated for Royalty Payments	15.00%	15.00%
Series A Convertible Preferred Stock [Member]
Issuance of shares	75,000

Liquidity (Details)

Liquidity (Details) - USD ($)	Mar. 02, 2021	Jul. 31, 2020	Jul. 10, 2020	Jul. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Financial Condition [Line Items]
Retained Earnings (Accumulated Deficit)					$ (112,312,441)						$ (112,312,441)		$ (105,563,124)
Net loss					(2,108,030)	$ (2,330,054)	$ (2,311,233)	$ (8,083,304)	$ (1,927,526)	$ (1,561,133)	(6,749,317)	$ (11,571,963)
Net Cash Provided by (Used in) Operating Activities											(5,986,138)	$ (4,957,235)
Revenue											0
Cash and cash equivalents					$ 22,899,518						$ 22,899,518		$ 13,708,594
Sales Agreement
Financial Condition [Line Items]
Commission rate		3.50%
Fees and disbursements of legal counsel in an amount not to exceed		$ 50,000
Amount not to exceed quarter during the term of sales agreement		2,500
Underwriting option
Financial Condition [Line Items]
Price of a share			$ 7.30
Net proceeds from the offering			$ 10,400,000
Shares issued			1,369,863
Additional shares			205,479
ATM Offering [Member] | Sales Agreement
Financial Condition [Line Items]
Price of a share	$ 7.83
Net proceeds from the offering	$ 6,100,000	$ 50,000,000		$ 50,000,000
Shares issued	814,242

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Warrants and Options (Details) - shares	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Line Items]
Total potentially outstanding dilutive common shares	14,146	27,505
Employee Stock Option [Member]
Accounting Policies [Line Items]
Total potentially outstanding dilutive common shares	5,000	5,000
Derivative liability - Old Warrants
Accounting Policies [Line Items]
Total potentially outstanding dilutive common shares	9,146	22,505

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Mar. 31, 2021USD ($)shares	Mar. 31, 2020shares	Jun. 30, 2020shares
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	14,146	27,505
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Preferred Stock, Shares Outstanding	371,103		368,602
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,298,861
Stockholders' Equity Note, Stock Split, Conversion Ratio	3.5
Percentage of Change of Control | $	$ 60

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Research and development	$ 1,464,177	$ 1,134,132	$ 4,530,448	$ 3,628,622
TheraCour
Property and Equipment	84,466		87,026	4,139
Account Payable - Related Party	583,075		583,075		$ 561,580
Research and development	$ 706,537	$ 601,016	$ 1,961,603	$ 1,720,311

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	Dec. 16, 2019	Nov. 01, 2019	Mar. 31, 2021	Jun. 30, 2020	Oct. 02, 2018
Related Party Transaction [Line Items]
Other General and Administrative Expense			$ 2,000
Percentage of Direct Costs			30.00%
Accrued Royalties			$ 0
TheraCour
Related Party Transaction [Line Items]
Percentage Of Net Sales Allocated For Royalty Payments		15.00%	15.00%
Series A Preferred stock
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares)	10,000
Series A Preferred stock | TheraCour
Related Party Transaction [Line Items]
Deferred monthly development fees					$ 25,000
Series A shares issued in exchange of deferred development fees owed (in shares)			1,074,075
Deferred development fees exchanged for shares			$ 491,000	$ 0

Related Party Transactions - Mo

Related Party Transactions - Mortgage Note Payable - Related Party (Details)	Dec. 16, 2019USD ($)itemshares	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jan. 01, 2021USD ($)	Jan. 01, 2020USD ($)
Related Party Transaction [Line Items]
Amount of loan							$ 235,476	$ 155,173
Amount of interest payable escrowed		$ 132,000			$ 132,000
Amount of interest expense which reduced the interest escrow retained by the lender		0		$ 33,367	62,773	$ 35,860
Series A Preferred stock
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares	10,000
Series A shares issued in exchange of deferred development fees owed	$ 39,301		$ 25,846		38,238
Converted value to common shares	3.5
Amortization expense on loan origination fee		0		$ 9,825	18,013	$ 11,463
Open End Mortgage Note | Dr. Anil Diwan
Related Party Transaction [Line Items]
Number of tranches | item	2
Amount of loan per tranche	$ 1,000,000
Interest rate per annum (as a percent)	12.00%
Drew down amount		$ 1,100,000			$ 1,100,000
Open End Mortgage Note | Dr. Anil Diwan | Maximum [Member]
Related Party Transaction [Line Items]
Amount of loan	$ 2,000,000

Property and Equipment - Proper

Property and Equipment - Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Property and Equipment
GMP Facility	$ 8,040,411	$ 8,020,471
Land	260,000	260,000
Office Equipment	57,781	57,781
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,885,223	5,756,956
Total Property and Equipment	14,249,024	14,100,815
Less Accumulated Depreciation	(5,074,669)	(4,556,384)
Property and Equipment, Net	$ 9,174,355	$ 9,544,431

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Property and Equipment
Depreciation	$ 174,076	$ 172,862	$ 522,172	$ 518,536

Trademark and Patents - Tradema

Trademark and Patents - Trademarks and Patents (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Trademarks and Patents
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(106,768)	(100,566)
Trademarks and Patents, Net	$ 352,186	$ 358,388

Trademark and Patents - Additio

Trademark and Patents - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Trademarks and Patents
Amortization	$ 2,067	$ 2,069	$ 6,202	$ 6,204

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Accrued expenses
Severance payment	$ 0	$ 21,000
Accrued payroll	24,228	38,240
Consultant	0	10,000
Accrued Expenses	$ 24,228	$ 69,240

Loan Payable (Details)

Loan Payable (Details) - USD ($)	Jan. 01, 2021	Jan. 01, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Loan Payable
Loan balance	$ 235,476	$ 155,173
Amount of loan repayment per month	$ 24,062	$ 15,874
Interest rate	4.74%	5.00%
Loan payable			$ 165,806		$ 165,806		$ 62,843
Interest expense			$ 2,516	$ 1,745	$ 3,282	$ 1,745

Equity Transactions - Proceeds

Equity Transactions - Proceeds of offering (Details)	Jul. 10, 2020USD ($)
Sales Agreement
Gross proceeds	$ 6,374,211
Less: offering costs and expenses	(252,730)
Net proceeds from issuance of common stock	6,121,481
Underwriting option
Gross proceeds	11,499,997
Less: offering costs and expenses	(1,057,781)
Net proceeds from issuance of common stock	$ 10,442,216

Equity Transactions - Fair Valu

Equity Transactions - Fair Value of Series A Preferred stock (Details) - Series A Preferred stock - USD ($)	Dec. 16, 2019	Jul. 11, 2018	Dec. 31, 2020	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross		26,250		2,501
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 39,301		$ 25,846	$ 38,238
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 3,155
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 2,391
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,898
Issuance Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,749
Issuance Date Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,596
Issuance Date Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,603
Issuance Date Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 1,632
Issuance Date Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 2,153
Issuance Date Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				1,340
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 19,744
Issuance Date Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				129
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 2,317

Equity Transactions - CEO (Deta

Equity Transactions - CEO (Details) - Chief Executive Officer [Member]	9 Months Ended
	Mar. 31, 2021
Expected life (year)	4 years
Expected annual rate of quarterly dividends	0.00%
Minimum [Member]
Expected volatility	91.10%
Risk-free rate(s)	0.24%
Maximum [Member]
Expected volatility	91.50%
Risk-free rate(s)	0.35%

Equity Transactions - Warrants

Equity Transactions - Warrants - Fair Value Assumptions (Details)	Mar. 31, 2021
Scientific Advisory Board Common Stock Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember

Equity Transactions - Additiona

Equity Transactions - Additional Information (Details) - USD ($)	Mar. 02, 2021	Jul. 31, 2020	Jul. 10, 2020	Jul. 08, 2020	Dec. 16, 2019	Jul. 11, 2018	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Class of Stock [Line Items]
Common shares sold											11,504,693		11,504,693		9,083,414
Common Stock, Par or Stated Value Per Share											$ 0.001		$ 0.001		$ 0.001
Underwriting option
Class of Stock [Line Items]
Common shares sold			1,369,863
Share Price			$ 7.30
Net proceeds from the offering			$ 10,400,000
Underwriters Option To Purchase Additional Shares, Number			205,479
Shares issued			1,369,863
Price of a share			$ 7.30
ATM Offering [Member] | Sales Agreement
Class of Stock [Line Items]
Net proceeds from the offering	$ 6,100,000	$ 50,000,000								$ 50,000,000
Shares issued	814,242
Price of a share	$ 7.83
Purchase Agreement With Institutional Investors [Member] | Underwriting option
Class of Stock [Line Items]
Underwriter's Option, Period To Avail Over Allotment Option				45 days
Stock Repurchase Program, Number of Shares Authorized to be Repurchased				1,369,863
Proceeds from Issuance Initial Public Offering				$ 7.30
Common Stock, Par or Stated Value Per Share				$ 0.001
Net proceeds from the offering				$ 10,400,000
Underwriters Option To Purchase Additional Shares, Number				205,479
Derivative liability - Old Warrants
Class of Stock [Line Items]
Allocated Share-based Compensation Expense											$ 1,750		$ 4,951
Number Of Common Stock To Be Issued Upon Conversion Of Warrants							572	572	572				572
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 6.05	$ 4.19	$ 6.86
Director [Member]
Class of Stock [Line Items]
Share-based Compensation											$ 15,000		$ 41,250
Stock Issued During Period, Shares, Share-based Compensation, Gross											3,300		9,446
Employee Compensations [Member]
Class of Stock [Line Items]
Share-based Compensation											$ 15,038		$ 15,038
Stock Issued During Period, Value, Share-based Compensation, Gross											3,572		3,572
Consulting Services [Member]
Class of Stock [Line Items]
Share-based Compensation											$ 27,000		$ 81,000
Stock Issued During Period, Shares, Share-based Compensation, Gross											6,131		18,677
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						33.33%
Employee Service Share-based Compensation, Non-vested Awards, Compensation Not yet Recognized, Stock Options														$ 45,654
Series A Convertible Preferred Stock [Member] | Forecast [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period														4,375
Series A Preferred stock
Class of Stock [Line Items]
Share-based Compensation											$ 45,654		$ 136,962
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 39,301							$ 25,846	$ 38,238
Stock Issued During Period, Shares, Share-based Compensation, Gross						26,250							2,501
Ratio of Converted Value To Common													3.50%
Series A Preferred stock | Minimum [Member]
Class of Stock [Line Items]
Share Price											$ 2.87		$ 2.87
Series A Preferred stock | Maximum [Member]
Class of Stock [Line Items]
Share Price											$ 9.97		$ 9.97
Series A Preferred stock | Employee Compensations [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross											$ 25,846		$ 38,238
Stock Issued During Period, Shares, Share-based Compensation, Gross											1,727		2,501

Stock Warrants and Options - St

Stock Warrants and Options - Stock Warrants (Details) - Stock Warrants - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and exercisable	22,218
Number of Shares, Granted	1,716
Number of Shares, Expired	14,788
Number of Shares, Outstanding and exercisable	9,146	22,218
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 30.82
Weighted Average Exercise Price per share, Granted (dollars per share)	5.36
Weighted Average Exercise Price per share, Expired (dollars per share)	39.16
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 12.34	$ 30.82
Weighted Average Remaining Contractual Term (years), Granted	0 years
Weighted Average Remaining Contractual Term (years), Expired	0 years
Weighted Average Remaining Contractual Term (years), Outstanding and exercisable	2 years	2 years 3 months 11 days
Aggregate Intrinsic Value, Outstanding and exercisable (in dollars)	$ 1,497	$ 4,533
Aggregate Intrinsic Value, Granted (in dollars)	0
Aggregate Intrinsic Value, Expired (in dollars)	$ 0

Stock Warrants and Options - _2

Stock Warrants and Options - Stock options (Details) - Equity Option - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and exercisable	5,000
Number of Shares, Granted	0
Number of Shares, Outstanding and exercisable	5,000	5,000
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 10
Weighted Average Exercise Price per share, Granted (dollars per share)	0
Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)	$ 10	$ 10
Weighted Average Remaining Contractual Term (years), Granted	0 years
Weighted Average Remaining Contractual Term (years), Outstanding and exercisable	5 months 1 day	1 year 1 month 28 days
Aggregate Intrinsic Value, Outstanding and exercisable (in dollars)	$ 0	$ 0
Aggregate Intrinsic Value, Granted (in dollars)	$ 0

Stock Warrants and Options - Ad

Stock Warrants and Options - Additional Information (Details)	9 Months Ended
	Mar. 31, 2021shares
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	569
June 30 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	2,287
June 30, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	2,287
June 30 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	2,287
June 30, 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	1,716

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Nov. 01, 2019	Jan. 01, 2015	May 30, 2013	Mar. 03, 2010	Mar. 31, 2021	Jun. 30, 2020
Commitments and Contingencies [Line Items]
Common stock, shares issued					11,504,693	9,083,414
Employment Agreement Term					3 years
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
TheraCour
Commitments and Contingencies [Line Items]
Stock Issued During Period, Shares, New Issues	75,000
Cash upon completion of Phase I Clinical Trials	$ 1,500,000
Cash upon completion of Phase II Clinical Trials	2,500,000
Cash upon completion of Phase III Clinical Trials	$ 5,000,000
Percentage of Net Sales Allocated for Royalty Payments	15.00%				15.00%
President And Board Of Directors, Chairman [Member]
Commitments and Contingencies [Line Items]
Base Salary					$ 400,000
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					26,250
President And Board Of Directors, Chairman [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
President And Board Of Directors, Chairman [Member] | Share-based Compensation Award, Tranche Two [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
President And Board Of Directors, Chairman [Member] | Share-based Compensation Award, Tranche Three [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					8,750
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued				1,786
Additional Common Stock Shares Issued				1,786
Increase In Base Salary				$ 150,000
Employment Agreement Term				4 years
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued				1,786
Additional Common Stock Shares Issued				1,786
Preferred stock, shares issued				1,340
Additional Preferred Stock Shares Issued				1,340
Increase In Base Salary				$ 150,000
Employment Agreement Term				4 years
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary		$ 10,800	$ 9,000
Employment Agreement Term			3 years
Chief Financial Officer [Member] | Series A Preferred stock
Commitments and Contingencies [Line Items]
Preferred stock, shares issued			129
Mr Taraporewala [Member]
Commitments and Contingencies [Line Items]
Percentage of Net Sales Allocated for Royalty Payments	15.00%